Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,963 DKK | +61.28% | +4.14% | +14.24% |
05:18pm | Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer | MT |
05:55am | Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment | MT |
Sales 2024 * | 19.67B 2.82B | Sales 2025 * | 23.53B 3.37B | Capitalization | 127B 18.25B |
---|---|---|---|---|---|
Net income 2024 * | 5.07B 726M | Net income 2025 * | 6.71B 961M | EV / Sales 2024 * | 5.14 x |
Net cash position 2024 * | 26.2B 3.75B | Net cash position 2025 * | 33.18B 4.75B | EV / Sales 2025 * | 4 x |
P/E ratio 2024 * |
25.5
x | P/E ratio 2025 * |
19.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
Latest transcript on Genmab
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
-3.18% | 102B | |
+1.63% | 96.29B | |
+2.13% | 22.18B | |
-15.60% | 21.2B | |
-39.98% | 17.38B | |
-15.75% | 16.36B | |
+4.77% | 13.97B | |
+32.23% | 12.17B | |
+309.43% | 8.32B |